SEC Form 4 · accession 0001493152-26-042754
AIM ImmunoTech Inc. · AIM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas K Equels
Officer — CEO & President · Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 15, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000946644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2026 | P | 5,900 | $0.219 | A | 69,822 | D |
Table II — derivative securities
No Table II lines on this filing.